research Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata
Ritlecitinib demonstrates clinically meaningful and sustained efficacy for over 1 year in treating alopecia areata (AA) in patients aged 12 years and older. The treatment also has a favorable safety and tolerability profile, supporting its long-term use.